Immunosuppression-state-of-the-art: Anything new in the pipeline?

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Purpose of review: Cardiac transplantation has been the therapy for advanced heart failure that is associated with the best and most durable outcomes. This has been a result of improvements in immunosuppression, specifically the widespread adoption of more potent immunosuppressive agents such as tacrolimus and mycophenolate mofetil in place of cyclosporine and azathioprine and more protocol-driven immunosuppressive regimens which minimize both rejection and complications of immunosuppression such as infections and nephrotoxicity. The rejection rates have fallen over the past 2 decades as posttransplant survival has improved. Despite these successes, long-term survival is limited by cardiac allograft vasculopathy and malignancies. The purpose of this review is to discuss new approaches to immunosuppression, which may address the long-term outcomes after transplant. Recent findings: Recent findings in clinical trials have shown that proliferation signal inhibitors or mammalian target of rapamycin inhibitors can reduce the incidence and severity of cardiac allograft vasculopathy and are used in higher doses as anticancer agents, but their uses are associated with side-effects. Summary: Consequently, there is considerable interest in developing newer immunosuppressive agents that will be more effective in treating and preventing these long-term complications with fewer side-effects. At present, there are no new agents other than Rituximab, which are being studied, in clinical trials.

Original languageEnglish (US)
Pages (from-to)500-507
Number of pages8
JournalCurrent Opinion in Organ Transplantation
Volume19
Issue number5
DOIs
StatePublished - Oct 1 2014

Fingerprint

Immunosuppressive Agents
Immunosuppression
Allografts
Clinical Trials
Mycophenolic Acid
Azathioprine
Tacrolimus
Sirolimus
Heart Transplantation
Antineoplastic Agents
Cyclosporine
Heart Failure
Transplants
Incidence
Infection
Neoplasms
Therapeutics

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Transplantation

Cite this

@article{b38f927347174595b52ae3800e3f0831,
title = "Immunosuppression-state-of-the-art: Anything new in the pipeline?",
abstract = "Purpose of review: Cardiac transplantation has been the therapy for advanced heart failure that is associated with the best and most durable outcomes. This has been a result of improvements in immunosuppression, specifically the widespread adoption of more potent immunosuppressive agents such as tacrolimus and mycophenolate mofetil in place of cyclosporine and azathioprine and more protocol-driven immunosuppressive regimens which minimize both rejection and complications of immunosuppression such as infections and nephrotoxicity. The rejection rates have fallen over the past 2 decades as posttransplant survival has improved. Despite these successes, long-term survival is limited by cardiac allograft vasculopathy and malignancies. The purpose of this review is to discuss new approaches to immunosuppression, which may address the long-term outcomes after transplant. Recent findings: Recent findings in clinical trials have shown that proliferation signal inhibitors or mammalian target of rapamycin inhibitors can reduce the incidence and severity of cardiac allograft vasculopathy and are used in higher doses as anticancer agents, but their uses are associated with side-effects. Summary: Consequently, there is considerable interest in developing newer immunosuppressive agents that will be more effective in treating and preventing these long-term complications with fewer side-effects. At present, there are no new agents other than Rituximab, which are being studied, in clinical trials.",
author = "Eisen, {Howard J.}",
year = "2014",
month = "10",
day = "1",
doi = "10.1097/MOT.0000000000000119",
language = "English (US)",
volume = "19",
pages = "500--507",
journal = "Current Opinion in Organ Transplantation",
issn = "1087-2418",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

Immunosuppression-state-of-the-art : Anything new in the pipeline? / Eisen, Howard J.

In: Current Opinion in Organ Transplantation, Vol. 19, No. 5, 01.10.2014, p. 500-507.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Immunosuppression-state-of-the-art

T2 - Anything new in the pipeline?

AU - Eisen, Howard J.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Purpose of review: Cardiac transplantation has been the therapy for advanced heart failure that is associated with the best and most durable outcomes. This has been a result of improvements in immunosuppression, specifically the widespread adoption of more potent immunosuppressive agents such as tacrolimus and mycophenolate mofetil in place of cyclosporine and azathioprine and more protocol-driven immunosuppressive regimens which minimize both rejection and complications of immunosuppression such as infections and nephrotoxicity. The rejection rates have fallen over the past 2 decades as posttransplant survival has improved. Despite these successes, long-term survival is limited by cardiac allograft vasculopathy and malignancies. The purpose of this review is to discuss new approaches to immunosuppression, which may address the long-term outcomes after transplant. Recent findings: Recent findings in clinical trials have shown that proliferation signal inhibitors or mammalian target of rapamycin inhibitors can reduce the incidence and severity of cardiac allograft vasculopathy and are used in higher doses as anticancer agents, but their uses are associated with side-effects. Summary: Consequently, there is considerable interest in developing newer immunosuppressive agents that will be more effective in treating and preventing these long-term complications with fewer side-effects. At present, there are no new agents other than Rituximab, which are being studied, in clinical trials.

AB - Purpose of review: Cardiac transplantation has been the therapy for advanced heart failure that is associated with the best and most durable outcomes. This has been a result of improvements in immunosuppression, specifically the widespread adoption of more potent immunosuppressive agents such as tacrolimus and mycophenolate mofetil in place of cyclosporine and azathioprine and more protocol-driven immunosuppressive regimens which minimize both rejection and complications of immunosuppression such as infections and nephrotoxicity. The rejection rates have fallen over the past 2 decades as posttransplant survival has improved. Despite these successes, long-term survival is limited by cardiac allograft vasculopathy and malignancies. The purpose of this review is to discuss new approaches to immunosuppression, which may address the long-term outcomes after transplant. Recent findings: Recent findings in clinical trials have shown that proliferation signal inhibitors or mammalian target of rapamycin inhibitors can reduce the incidence and severity of cardiac allograft vasculopathy and are used in higher doses as anticancer agents, but their uses are associated with side-effects. Summary: Consequently, there is considerable interest in developing newer immunosuppressive agents that will be more effective in treating and preventing these long-term complications with fewer side-effects. At present, there are no new agents other than Rituximab, which are being studied, in clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=84925808996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925808996&partnerID=8YFLogxK

U2 - 10.1097/MOT.0000000000000119

DO - 10.1097/MOT.0000000000000119

M3 - Review article

C2 - 25160696

AN - SCOPUS:84925808996

VL - 19

SP - 500

EP - 507

JO - Current Opinion in Organ Transplantation

JF - Current Opinion in Organ Transplantation

SN - 1087-2418

IS - 5

ER -